Fidelity Disruptive Medicine ETF (FMED)
| Assets | $49.45M |
| Expense Ratio | 0.50% |
| PE Ratio | 40.21 |
| Forward PE | 31.04 |
| Shares Out | 1.62M |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 4,873 |
| Open | 30.80 |
| Previous Close | 30.64 |
| Day's Range | 30.80 - 31.32 |
| 52-Week Low | 23.48 |
| 52-Week High | 32.99 |
| Beta | 0.77 |
| Holdings | 78 |
| Inception Date | Apr 16, 2020 |
About FMED
Fund Home PageThe Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is issued by Fidelity.
Top 10 Holdings
39.71% of assets| Name | Symbol | Weight |
|---|---|---|
| Fidelity Securities Lending Cash Central Fund | n/a | 7.03% |
| 10x Genomics, Inc. | TXG | 4.77% |
| Natera, Inc. | NTRA | 4.44% |
| Thermo Fisher Scientific Inc. | TMO | 4.33% |
| Danaher Corporation | DHR | 4.06% |
| Illumina, Inc. | ILMN | 3.71% |
| Sartorius Stedim Biotech S.A. | DIM | 2.91% |
| LifeStance Health Group, Inc. | LFST | 2.88% |
| Revolution Medicines, Inc. | RVMD | 2.80% |
| Moderna, Inc. | MRNA | 2.77% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 20, 2024 | $0.112 | Dec 24, 2024 |
| Jun 21, 2024 | $0.001 | Jun 25, 2024 |
Performance
FMED had a total return of 21.56% in the past year, including dividends. Since the fund's inception, the average annual return has been 6.97%.
News
Fidelity Investments® Announces Liquidation of Five Exchange-Traded Funds
BOSTON--(BUSINESS WIRE)--Fidelity Investments® today announced the upcoming liquidation of five exchange-traded funds (ETFs): Fidelity Disruptive Finance ETF (FDFF), Fidelity Disruptive Medicine ETF (...
Why traditional active managers are joining the ETF space
Greg Friedman, head of ETF management and strategy at Fidelity Investments, joins 'Halftime Report' to discuss a spike in ETF flows going to active management, Fidelity's decision to convert mutual fu...